Results 131 to 140 of about 2,408 (179)

An update on LDL apheresis for nephrotic syndrome

Pediatric Nephrology, 2018
Low-density lipoprotein (LDL) apheresis has been used increasingly in clinical practice for the treatment of renal diseases with nephrotic syndrome (NS), specifically focal segmental glomerulosclerosis (FSGS). Persistent hyperlipidemia for prolonged periods is nephrotoxic and leads to chronic progressive glomerular and tubulointerstitial injury ...
Rupesh Raina, Vinod Krishnappa
openaire   +2 more sources

Applications of LDL-apheresis in nephrology

Clinical and Experimental Nephrology, 2008
LDL-apheresis (LA) was originally used for familial hyperlipidemia, and then in Japan extended to use for the treatment of patients with peripheral arterial disease (PAD) and nephrotic syndrome due to steroid-resistant focal glomerular sclerosis (FGS). The reason why this treatment is applicable for these disorders is due to the fact that LA exerts its
openaire   +2 more sources

Recommendations for the use of LDL apheresis

Atherosclerosis, 2008
Plasma exchange has been shown to increase life-expectancy in homozygous familial hypercholesterolaemia (FH) but increasingly is being replaced by LDL apheresis. Several methods are now available for undertaking this procedure, which lowers LDL cholesterol and Lp(a) efficiently and safely when performed weekly or bi-weekly and causes only slight ...
openaire   +2 more sources

Activation of coagulation by a LDL-apheresis device

Blood Coagulation & Fibrinolysis, 1996
LDL-apheresis often induces an almost constant and progressive increase of the differential pressure of plasma flowing through the dextran sulphate cellulose column, reducing the efficacy of the treatment. On two occasions we were able to identify a fibrin plug by immunofluorescence. Our aim was to verify the modification of some coagulation indicators
C, Giansante, P, Bordin, N, Fiotti, S, Calabrese, A, Petrucco, P G, Da Col, M, Fonda, L, Cattin   +7 more
openaire   +2 more sources

Role of LDL apheresis in the management of hypercholesterolaemia

Transfusion Science, 1993
Abstract It is now established that extracorporeal cholesterol removal is the best means of improving prognosis in patients with homozygous FH and this should be started before atherosclerosis becomes apparent. Anti-human LDL antibodysepharose columns, dextran sulphate-cellulose gel columns and the HELP system are all potent methods of extracorporeal
Y, Kitano, G R, Thompson
openaire   +2 more sources

Overview: Techniques and Indications of LDL-Apheresis

Biomaterials, Artificial Cells and Immobilization Biotechnology, 1991
In recent years, LDL-apheresis has emerged to be an efficient treatment of hyperlipidemia in patients who do not respond sufficiently to diet and lipid lowering drugs. A survey of LDL lowering extracorporeal procedures is presented. Among them, to date 5 procedures have been used clinically on a routine basis: unselective plasma exchange, semi ...
T, Bosch, H J, Gurland
openaire   +2 more sources

Organization and Technical Problems of LDL-apheresis

The International Journal of Artificial Organs, 1993
The Authors consider problems related to technique and organization of LDL-Apher-esis with respect to some particular aspects. They evaluate: a) Technical complexity of procedures both in devices to use and in staff preparation; b) Length of treatment which conditions the other fields of activity; c)
N, Scarpato, C, Falco, G, Nappi, S, Formisano   +3 more
openaire   +2 more sources

[Plaque stabilization by LDL apheresis?].

Herz, 1999
Vulnerable lipid-rich plaques are often the cause of atherothrombotic events leading to unstable angina and/or to acute myocardial infarction. Consequent long-term LDL-lowering by drugs as shown by the most important intervention studies lead to plaque stabilization as shown by the significant reduction of myocardial reinfarction.
P, Schuff-Werner, V, Schettler
openaire   +2 more sources

[LDL apheresis: an update and overview. LDL apheresis in Sardinia, Italy (SMILDLa)].

Giornale italiano di nefrologia : organo ufficiale della Societa italiana di nefrologia, 2012
LDL apheresis (LDLa) is an invasive therapeutic tool to control qualitative and quantitative disorders of lipid metabolism. It is aimed at achieving a metabolic balance in association with lipid-lowering drugs in patients with severe, genetically determined or acquired dyslipidemia who do not reach clinically adequate LDL-cholesterol (LDL-C) levels (
Claudia, Stefanutti, Serafina, Di Giacomo, Claudia, Morozzi   +2 more
openaire   +1 more source

LDL apheresis as it relates to nursing practice

Transfusion and Apheresis Science, 2017
Nurses are an essential partner in the treatment of complex diseases and they have extensive influence on patient outcomes. Connecting a patient to a machine takes courage, skill, and a whole lot of trust. Anyone who has earned the title of "nurse" has shown courage. Skill comes with hours and hours of practice. Trust is earned and ongoing.
openaire   +2 more sources